Výsledky vyhledávání - "Nicolae Ghilezan"

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Publikováno v: Lung Cancer. 52:155-163

The primary objective of this randomized phase III study was to show significant difference in median time to progression (TTP) in patients with advanced NSCLC treated with single-agent gemcitabine maintenance therapy versus best supportive care foll

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aedaf319ec119045340dabe47d954e90
https://doi.org/10.1016/j.lungcan.2006.01.006

Zobrazit plný text záznamu

Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial

Autor: George Fountzilas, Anna Kalogera-Fountzila, Maria-Ekaterini Theofanopoulou, I. Sofroniadis, Afroditi Haritanti, Elisabeta Ciuleanou, Nicolae Ghilezan, Nikolaos Zamboglou, Athanasios Dimitriadis, George A. Plataniotis

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 59:1018-1026

Purpose Tumor volume (TV) is one of the main reported factors determining the outcome of treatment in head-and-neck carcinomas. In this study, the prognostic impact of TV was explored in the context of a randomized trial with the patients assigned to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a351553292d482aaa3e0b1c3bb2bc8c8
https://doi.org/10.1016/j.ijrobp.2004.01.021

Zobrazit plný text záznamu

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicentric, prospective, randomized phase III trial

Background The objectives of this phase III trial were to compare the time to progressive disease (TtPD), overall response rate (ORR), overall survival, and toxicity of gemcitabine, epirubicin, and paclitaxel (GET) versus fluorouracil (FU), epirubici

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c77cfa382e3eb40690fa2f3e63a1fe2a
https://www.bib.irb.hr/230572

Zobrazit plný text záznamu

Gemcitabine and cisplatin (GC) +/− subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG)

Autor: Thomas Brodowicz, Christoph C. Zielinski, E. Ulsperger, Matjaz Zwitter, Valentina Tzekova, Maciej Krzakowski, B. Cucevic, Nicolae Ghilezan, M. Wenczl, Rodryg Ramlau

Publikováno v: Journal of Clinical Oncology. 22:7067-7067

7067 Background: The optimal treatment duration for NSCLC patients is still a matter of discussion. Objectives of this trial were to compare time to progressive disease (TTPD) in patients treated w...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80b813f729314c1c445e24a76c69ad26
https://doi.org/10.1200/jco.2004.22.90140.7067

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání